End-to-End Antibody Discovery: From NGS and Assay Data to Therapeutic Leads
In today’s fast‑moving therapeutic landscape, researchers face a critical bottleneck: prioritizing lead candidates without getting slowed down by complex bioinformatics pipelines. Join us for an insightful webinar where we’ll showcase how to accelerate the end-to-end workflow and prioritize leads faster than ever.
What you’ll learn:
How to perform clustering and motif-level analysis to uncover emergent clones and immune responses across selection rounds
Techniques to track enrichment and liabilities, monitor clone dynamics over time or between arms (immunization, treatment, timepoint), and identify convergent B-cell responses
Approaches to model antibody structure and predict affinity directly from sequence data, enabling prioritization of candidates based on developability
Real-world workflows for lead selection, efficiently moving from hundreds or thousands of sequences to best-in-class antibody leads without coding
Insights into how top pharma/biotech teams streamline antibody discovery and optimize their workflows for faster results
Who should attend:
Biologists, immunologists, scientists working on antibody discovery
Bioinformaticians and computational biologists seeking to reduce bottlenecks in their analysis
Project leads and decision‑makers in biotech/pharma who want to streamline the antibody‑lead pipeline, reduce risk and time‑to‑lead